With close ties to University of Utah, SAB Capra, LLC is a privately-held, emerging bioscience company using transgenic goats to produce human polyclonal antibodies for use in diagnostics and testing, targeted immunotherapies and personalized medicine applications. With the initial work in the firm supported by the Utah Science Technology and Research (USTAR) Initiative, a technology based economic development initiative funded by the state of Utah, the company is a wholly owned subsidiary of SAB Biotherapeutics, Inc., which is pioneering the development and use of large transgenic animals for the production of targeted human polyclonal antibodies with their novel DiverstAb⢠immunotherapy platform
